# Real-Data Validation and Master Brain Execution

**Workspace:** `pradeepaiperio`  
**Data policy:** observed public pan-cancer data only; no synthetic biological samples

## All-33-project TCGA cohort completed

The GDC index contains 3,086 open-access STAR-count RNA-seq files spanning all 33 TCGA
projects. A balanced cohort of 330 files downloaded with zero failures (10 per project) and
was harmonised into count and TPM matrices covering 60,660 genes. Quantisation generated
165,000 expression state-token rows across 500 variable genes and all 330 samples.

## Real validation completed

The validation action used 1,066 DepMap models and produced:

- 100 candidate-gene permutation tests with 200 observed-value permutations per gene;
- 2,000 expression–dependency results across 20 sufficiently represented cancer lineages;
- 615 PRISM drug–target pairs, of which 614 passed automated metadata support checks;
- 1,033 lineage-specific dependency–pharmacology results.

Permutations rearranged observed dependency values solely to form empirical null distributions.
They did not generate artificial cancer samples.

## First real Master Brain completed

The Master integrated three independently reduced observed-data streams:

1. DepMap expression;
2. DepMap CRISPR dependency;
3. PRISM pharmacology.

The shared analysis contained 723 models across 29 lineage labels. For every model, the system
retained modality-specific agent states, within-agent instability, inter-agent disagreement,
counterfactual agent influence, Master uncertainty, meta-uncertainty and an explicitly labeled
empirical multi-modal cancer-instability proxy.

The execution wrote 2,169 agent-integration transition events with trace completeness 1.0.

## Independent GDSC replication completed

Official Sanger GDSC1/GDSC2 fitted-response releases supplied 575,197 observed response rows.
Exact Sanger model identifiers mapped 322,040 rows and 531 cell-line models to DepMap. Of 614
unique PRISM/CRISPR drug-target pairs, 166 had the same drug in GDSC and a measured CRISPR
target. Effect direction was concordant for 109/147 GDSC1 tests (74.1%), 85/114 GDSC2 tests
(74.6%), and 125/166 pooled tests (75.3%). The corresponding PRISM-versus-GDSC Pearson
effect-size correlations were 0.751, 0.754 and 0.775.

These are cross-dataset association results, not proof of causal drug response or clinical
validity. All values came from observed public DepMap, PRISM and GDSC data.

## LINCS matched-time future-state audit completed

The checksum-verified NCBI GEO GSE70138 Level-5 matrix contains 118,050 signatures by 12,328
genes. Cancer filtering retained 89,192 signatures and all 978 directly measured landmark
genes. Exact matching by cancer cell, perturbation, dose and perturbation type produced 3,675
observed transitions across 3 h, 6 h and 24 h states.

The frozen audit withheld 24 complete perturbation identifiers, yielding 712 test transitions.
Three agents (ridge, random forest and nearest neighbours) generated forecasts, and a Master
combined them using calibration-only reliability weights. The execution retained separately:

1. observed cancer future-state change;
2. each agent's holdout error;
3. inter-agent disagreement;
4. Master holdout error;
5. calibrated Master self-uncertainty and its meta-calibration error.

The 2,136 O0-O6 holdout events had trace completeness 1.0. State reconstructability was 0.223,
recursive consistency was 0.568, Master RMSE was 0.871 and uncertainty-error correlation was
0.615. OSIC was 0.895: large observed biological transitions were strongly associated with
larger Master errors. This is a falsification-relevant limitation of the present forecaster, not
evidence of successful clinical prediction.

A frozen exploratory null specification then tested nine channel pairs with Pearson, Spearman
and quantile-normalized mutual information. With 1,000 observed-value permutations and
Benjamini–Hochberg correction, the cancer-change/Master-error association survived for Pearson
(0.895), Spearman (0.799) and normalized mutual information (0.265); each had empirical
`p = 0.001` and `FDR = 0.001`. This confirms structured error coupling, not forecast accuracy.

## TCGA real patient-outcome audit completed

The official GDC TCGA-CDR supplied 11,160 patient records across all 33 projects and linked to
all 330 harmonised RNA files. A censoring-aware two-year overall-survival endpoint retained 227
unique baseline-tumor patients across all 33 projects. Complete cancer projects were frozen into
fit, calibration and test partitions; the test partition contained 42 patients from seven cancer
projects that were absent from fitting and calibration.

After correcting the exact-horizon censoring edge case, the Master achieved AUROC 0.677 and
Brier 0.215, versus 0.239 for a fit-prevalence baseline. Observed-label permutation p-values
were 0.0270 for AUROC and 0.0360 for Brier. This supports the fixed small holdout but is not
external clinical validation. The 126 transitions had trace completeness 1.0. OSIC was 0.896
(`p = 0.000999`), but the self-observer failed to generalize: error correlation was -0.267 and
recursive consistency was 0.436. The result supports observability of a failure mode, not
clinical readiness.

## Recursive observability profile

| Dimension | Prototype value |
|---|---:|
| State reconstructability | 0.998511 |
| Trace completeness | 1.000000 |
| Agent influence identifiability | 1.000000 |
| Uncertainty visibility | 1.000000 |
| Meta-uncertainty observability | 1.000000 |
| Recursive consistency | 0.955834 |

The observed prototype OSIC correlation was 0.270965. This is an engineering measurement on a
cross-sectional instability proxy, not evidence that AI instability captures true temporal
cancer future-state instability. That claim requires external temporal and perturbational data.

## Remote artifacts

```text
/pancancer/results/validation/real_data_validation_summary.json
/pancancer/results/validation/lineage_expression_dependency.csv
/pancancer/results/validation/expression_dependency_permutation_nulls.csv
/pancancer/results/validation/curated_drug_target_pairs.csv
/pancancer/results/validation/lineage_dependency_pharmacology.csv
/pancancer/results/master_brain/real_agent_states.parquet
/pancancer/results/master_brain/real_master_states.parquet
/pancancer/results/master_brain/recursive_observability_events.jsonl
/pancancer/results/master_brain/recursive_observability_report.json
/pancancer/results/validation/gdsc_external_replication/prism_crispr_gdsc_replication.csv
/pancancer/results/validation/gdsc_external_replication/gdsc_external_replication_summary.json
/pancancer/results/validation/lincs_future_state/lincs_future_state_recursive_observability_report.json
/pancancer/results/validation/lincs_future_state/frozen_holdout_transition_audit.parquet
/pancancer/results/validation/lincs_future_state/frozen_holdout_recursive_events.jsonl
/pancancer/results/validation/lincs_future_state/nonlinear_observability_null_tests.csv
/pancancer/results/validation/lincs_future_state/frozen_nonlinear_null_specification.json
/pancancer/results/tcga_outcome_observability/tcga_outcome_observability_report.json
/pancancer/results/tcga_outcome_observability/heldout_project_predictions.parquet
/pancancer/results/tcga_outcome_observability/recursive_observability_events.jsonl
```

## Interpretation boundary

This run establishes that the proposed recursive observability architecture is executable and
reconstructable on real public pan-cancer observations. It does not establish clinical validity,
causal drug response, biological consciousness, repeated patient molecular-state prediction or
clinical utility.
